Literature DB >> 11590123

Disabled early recruitment of antioxidant defenses in Friedreich's ataxia.

K Chantrel-Groussard1, V Geromel, H Puccio, M Koenig, A Munnich, A Rötig, P Rustin.   

Abstract

Friedreich's ataxia (FRDA) results from a generalized deficiency of mitochondrial iron-sulfur protein activity ascribed to mitochondrial iron overload. However, iron overload appears to be a late event in the disease. Here we show that neither superoxide dismutases nor the import iron machinery was induced by an endogenous oxidative stress in FRDA patients' fibroblasts in contrast to control cells. Superoxide dismutase activity was not induced in the heart of conditional frataxin-KO mice either. This suggests that continuous oxidative damage to iron-sulfur clusters, resulting from hampered superoxide dismutase signaling, is causative of the mitochondrial deficiency and long term mitochondrial iron overload occurring in FRDA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11590123     DOI: 10.1093/hmg/10.19.2061

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  73 in total

1.  Cardiac hypertrophy and oxidative stress: a leap of faith or stark reality?

Authors:  D Lang
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

Review 2.  Friedreich ataxia-update on pathogenesis and possible therapies.

Authors:  Max Voncken; Panos Ioannou; Martin B Delatycki
Journal:  Neurogenetics       Date:  2003-12-19       Impact factor: 2.660

3.  Defects in mitochondrial axonal transport and membrane potential without increased reactive oxygen species production in a Drosophila model of Friedreich ataxia.

Authors:  Yujiro Shidara; Peter J Hollenbeck
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

4.  Co-precipitation of phosphate and iron limits mitochondrial phosphate availability in Saccharomyces cerevisiae lacking the yeast frataxin homologue (YFH1).

Authors:  Alexandra Seguin; Renata Santos; Debkumar Pain; Andrew Dancis; Jean-Michel Camadro; Emmanuel Lesuisse
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

Review 5.  Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments.

Authors:  Ngolela E Babady; Nadege Carelle; Robert D Wells; Tracey A Rouault; Michio Hirano; David R Lynch; Martin B Delatycki; Robert B Wilson; Grazia Isaya; Hélène Puccio
Journal:  Mol Genet Metab       Date:  2007-06-26       Impact factor: 4.797

6.  Modeling of Friedreich ataxia-related iron overloading cardiomyopathy using patient-specific-induced pluripotent stem cells.

Authors:  Yee-Ki Lee; Philip Wing-Lok Ho; Revital Schick; Yee-Man Lau; Wing-Hon Lai; Ting Zhou; Yanhua Li; Kwong-Man Ng; Shu-Leung Ho; Miguel Angel Esteban; Ofer Binah; Hung-Fat Tse; Chung-Wah Siu
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

7.  Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of Idebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich Ataxia.

Authors:  Matthias L Jauslin; Silvia Vertuani; Elisa Durini; Lisa Buzzoni; Nunzia Ciliberti; Sara Verdecchia; Paola Palozza; Thomas Meier; Stefano Manfredini
Journal:  Mol Cell Biochem       Date:  2007-05-03       Impact factor: 3.396

Review 8.  Therapeutic strategies in Friedreich's ataxia.

Authors:  Timothy E Richardson; Heather N Kelly; Amanda E Yu; James W Simpkins
Journal:  Brain Res       Date:  2013-04-13       Impact factor: 3.252

9.  Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen.

Authors:  Nadège Calmels; Hervé Seznec; Pascal Villa; Laurence Reutenauer; Marcel Hibert; Jacques Haiech; Pierre Rustin; Michel Koenig; Hélène Puccio
Journal:  BMC Neurol       Date:  2009-08-24       Impact factor: 2.474

10.  The first cellular models based on frataxin missense mutations that reproduce spontaneously the defects associated with Friedreich ataxia.

Authors:  Nadège Calmels; Stéphane Schmucker; Marie Wattenhofer-Donzé; Alain Martelli; Nadège Vaucamps; Laurence Reutenauer; Nadia Messaddeq; Cécile Bouton; Michel Koenig; Hélène Puccio
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.